SNBP News and Press, Sun BioPharma Inc

MINNEAPOLIS, Dec. 08, 2020 (GLOBE NEWSWIRE) --  Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, has completed patient enrollment in its Phase 1 trial evaluating the s...

MINNEAPOLIS, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Sun BioPharma, Inc. (Nasdaq: SNBP), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, has announced the change of its corporate name to Panbela Therapeutics, Inc. effective ...

Sun BioPharma (SNBP): Q3 GAAP EPS of -$0.21 misses by $0.09.Cash of $10.9MPress Release For further details see: Sun BioPharma EPS misses by $0.09

MINNEAPOLIS, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Sun BioPharma, Inc. (Nasdaq: SNBP), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with pancreatic cancer, today provides a business update and reports financial results for the quart...

MINNEAPOLIS, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Sun BioPharma, Inc. (Nasdaq:SNBP), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with pancreatic cancer, today announced it will participate in the 11th Annual Craig-Hallum Alpha...

MINNEAPOLIS, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Sun BioPharma, Inc. (Nasdaq:SNBP), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with pancreatic cancer, today announced that it will host a conference call on November 12, 2020 at 4...

MINNEAPOLIS, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Sun BioPharma, Inc. (Nasdaq:SNBP), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with pancreatic cancer, today announced the closing of its previously announced underwritten public ...

Sun BioPharma ( OTCQB:SNBP ) has priced public offering of 2,545,454 common stock and the same number of warrants at $4.125/share and warrant, for gross proceeds of ~$10.5M . More news on: Sun BioPharma, Inc., Healthcare stocks news, , Read more ...

MINNEAPOLIS, Aug. 28, 2020 (GLOBE NEWSWIRE) -- Sun BioPharma, Inc. (OTCQB:SNBP Nasdaq:SNBP), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with pancreatic cancer, today announced the pricing of an underwritten public offering o...

Quick Take Sun BioPharma (SNBP) intends to raise $10 million from the sale of its common stock in an IPO, according to an amended registration statement . The company is developing a treatment candidate for pancreatic cancer. SNBP is a thinly capitalized firm operating in a very difficu...